UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051633
Receipt number R000058894
Scientific Title A randomized, double-blind, placebo-controlled, parallel-group comparative study on the effect of continuous intake of the test food on visceral fat in healthy adult men and women
Date of disclosure of the study information 2023/07/23
Last modified on 2023/07/18 15:10:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Verification of the effects of continuous intake of the test food on visceral fa

Acronym

Verification of the effects of continuous intake of the test food on visceral fat

Scientific Title

A randomized, double-blind, placebo-controlled, parallel-group comparative study on the effect of continuous intake of the test food on visceral fat in healthy adult men and women

Scientific Title:Acronym

A randomized, double-blind, placebo-controlled, parallel-group comparative study on the effect of continuous intake of the test food on visceral fat in healthy adult men and women

Region

Japan


Condition

Condition

healthy adult men and women

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to examine the effect of test food intake on visceral fat area.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

visceral fat area

Key secondary outcomes

Weight, BMI, waist circumference, hip circumference


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Continuous intake of the test food for 12 weeks

Interventions/Control_2

Continuous intake of control food for 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

1) Japanese men and women aged between 20 and 60 at the time of obtaining written consent
2) Persons with a BMI of 23 or more and less than 30
3) Subjects who have received a sufficient explanation of the purpose and content of the research, are capable of giving consent, have fully understood the study, voluntarily applied to participate in the study, and agreed to participate in the study in writing.

Key exclusion criteria

1.show severe allergy to the test food
2.with an implantable defibrillator such as a pacemaker
3.have a current or a history of skin diseases,
4.develop severe allergy to metals
5.with severe anemia
6.Currently pregnant or breastfeeding. Or a person who may have such a possibility during the test period
7.Liver/kidney/cardiac disease, respiratory disorder, endocrine disorder, metabolic disorder, neurological disorder, consciousness disorder, diabetes, brain disease, malignant tumor, immune disease, serious disease such as heart disease, thyroid disease, other metabolic diseases Those who have a serious current disease such as disease or a history
8.are currently undergoing drug treatment, outpatient treatment, diet therapy, or exercise therapy for any serious or chronic disease.
9.are aware of dysmenorrhea or PMS symptoms
10.using health foods, supplements, and medicines that affect test results
11.with current or past drug or alcohol dependence
12.are undergoing hospital visits due to mental disorders (depression, etc.), sleep disorders, etc., or have a history of mental disorders in the past
13.with irregular life rhythm due to night work or shift work
14.lifestyle habits may change during the period from the preliminary examination
15.with extremely irregular lifestyles such as eating and sleeping
16.have an extremely unbalanced diet
17.participated in other clinical trials (research) within 3 months prior to the date of consent acquisition, or those who plan to participate in other clinical trials (research) during the trial period
18.have collected or donated more than 200 mL of blood within 1 month or 400 mL of blood within 3 months prior to the date of obtaining informed consent
19.have difficulty keeping track of various questionnaires
20.judged to be unsuitable as subjects based on clinical test values and measured values at the time of SCR
21.are judged to be inappropriate as subjects by the principal investigator

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Daisuke
Middle name
Last name Ochitani

Organization

BHN Co., Ltd

Division name

EBF Business Promotion Office

Zip code

101-0054

Address

1-16, Kanda Nishiki-cho, Chiyoda-ku, Tokyo,, Japan

TEL

03-5281-5661

Email

d-ochitani@bhn.co.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name Ochitani

Organization

BHN Co., Ltd

Division name

EBF Business Promotion Office

Zip code

101-0054

Address

1-16, Kanda Nishiki-cho, Chiyoda-ku, Tokyo, Japan

TEL

03-5281-5661

Homepage URL


Email

d-ochitani@bhn.co.jp


Sponsor or person

Institute

BHN Co., Ltd

Institute

Department

Personal name



Funding Source

Organization

Jinmon Co., Ltd

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shiba Palace Clinic Ethics Review Committee

Address

DaiwaA Hamamatsucho Bldg. 6F, 1-9-10, Hamamatsucho Minato-ku, Tokyo

Tel

03-5408-1599

Email

shiba_palace@s-palace-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 07 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 07 Month 13 Day

Date of IRB

2023 Year 07 Month 03 Day

Anticipated trial start date

2023 Year 07 Month 24 Day

Last follow-up date

2023 Year 11 Month 24 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 07 Month 18 Day

Last modified on

2023 Year 07 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058894


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name